{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:04:28Z","timestamp":1760598268933,"version":"3.41.2"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Secretoneurin (SN) is a neuropeptide with potential utility as a biomarker of cardiovascular episodes. The main effect of SN is mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences calcium handling. We aimed to associate the levels of SN in plasma with different causes of heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. SN was analysed from venous blood by use of the ELISA method. SN plasma levels were compared in DCM, ICM and healthy individuals with non-parametric tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 53 patients (81.1% male, 18.9% female; mean age 67.9\u2009\u00b1\u200912.6 years) and 34 healthy individuals (38% male, 62% female) were included in the analysis. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8\u2009\u00b1\u200927\u2005pmol\/L) as compared with the ischaemic cardiomyopathy (19.7\u2009\u00b1\u200922.6\u2005pmol\/L) group (<jats:italic>P<\/jats:italic>\u2009=\u20090.006). There was no significant difference between females vs. males (27.1\u2009\u00b1\u200923 vs. 25.5\u2009\u00b1\u200926.2\u2005pmol\/L, <jats:italic>P<\/jats:italic>\u2009=\u2009NS). Plasma SN levels allowed DCM and ICM to be differentiated with 88% sensitivity and 61% specificity (<jats:italic>P<\/jats:italic>\u2009=\u20090.007), the cut of value is 13.3\u2005pmol\/L. Plasma SN levels differed significantly between healthy volunteers and both ICM (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.0001) and DCM (<jats:italic>P<\/jats:italic>\u2009=\u20090.049). Plasma SN levels did not differ according to age and were not associated with comorbidities, left ventricular ejection fraction, heart failure medication, troponin, creatinine, or natriuretic peptide plasma levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Plasma secretoneurin levels differed significantly in DCM vs. ICM, being higher in the former. Based on plasma SN levels, discrimination between DCM and ICM might be possible. Healthy individuals produce higher SN plasma levels than stable HFrEF patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1297900","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T05:39:15Z","timestamp":1704692355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Secretoneurin levels are higher in dilated cardiomyopathy than in ischaemic cardiomyopathy: preliminary results"],"prefix":"10.3389","volume":"10","author":[{"given":"Ji\u0159\u00ed","family":"Pl\u00e1\u0161ek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozef","family":"Dodul\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Laz\u00e1rov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zden\u011bk","family":"\u0160vagera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nela","family":"Chobolov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"\u0160ulc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"Evin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Purov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"V\u00e1clav\u00edk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jacc.2014.11.028","article-title":"Will secretoneurin be the next big thing","volume":"65","author":"Anderson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.3390\/jcm11237191","article-title":"Secretoneurin as a novel biomarker of cardiovascular episodes: are we there yet? A narrative review","volume":"11","author":"Pl\u00e1\u0161ek","year":"2022","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2014.10.065","article-title":"Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling","volume":"65","author":"Ottesen","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","article-title":"Mechanisms of altered Ca2+ handling in heart failure","volume":"113","author":"Luo","year":"2013","journal-title":"Circ Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"110595","DOI":"10.1016\/j.clinbiochem.2023.110595","article-title":"Prognostic value of secretoneurin in chronic heart failure. Data from the GISSI-heart failure trial","volume":"118","author":"R\u00f8sj\u00f8","year":"2023","journal-title":"Clin Biochem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clinbiochem.2021.09.014","article-title":"Biologial variation of secretoneurin; a novel cardiovascular biomarker implicated in arrhythmogenesis","volume":"98","author":"Aakre","year":"2021","journal-title":"Clin Biochem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ejhf.2927","article-title":"Secretoneurin plasma levels in patients with different etiologies of heart failure: preliminary data\u2014abstracts of the heart failure 2023 and the world congress on acute heart failure, 20\u201323 May 2023, Prague, Czechia","volume":"25","author":"Dodul\u00edk","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"B8","doi-asserted-by":"publisher","first-page":"007045","DOI":"10.1161\/CIRCEP.118.007045","article-title":"Secretoneurin is an endogenous CaMKII inhibitor that attenuates Ca2+-dependent arrhythmia","volume":"12","author":"Ottesen","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1097\/CCM.0000000000003670","article-title":"Circulating secretoneurin concentrations after cardiac surgery: data from the FINNish acute kidney injury heart study","volume":"47","author":"Brynildsen","year":"2019","journal-title":"Crit Care med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clinbiochem.2019.06.008","article-title":"Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis","volume":"71","author":"Brynildsen","year":"2019","journal-title":"Clin Biochem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1097\/CCM.0000000000001832","article-title":"Prognostic value of secretoneurin in critically ill patients with infections","volume":"44","author":"R\u00f8sj\u00f8","year":"2016","journal-title":"Crit Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"ehac544.912","DOI":"10.1093\/eurheartj\/ehac544.912","article-title":"Circulating secretoneurin concentrations provide independent prognostic information to established risk indices in patients with chronic heart failure","volume":"43","author":"Rosjo","year":"2022","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ehf2.12071","article-title":"Biomarkers in heart failure: the importance of inconvenient details","volume":"3","author":"Miller","year":"2016","journal-title":"ESC Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yjmcc.2022.02.003","article-title":"Changes in extracellular matrix in failing human non-ischemic nad ischemic hearts with mechanical unloading","volume":"166","author":"Zhao","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1253\/circj.71.186","article-title":"Serum amyloid A is a better predictor of clinical outcomes than C-reative protein in non-ST-segment elevation acute coronary syndromes","volume":"71","author":"Kosuge","year":"2007","journal-title":"Circ J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2011.06.001","article-title":"Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without stable coronary artery disease\u2014results from the ludwigshafen risk and cardiovascular health study (LURIC)","volume":"219","author":"Lepper","year":"2011","journal-title":"Atherosclerosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/CIRCRESAHA.119.311148","article-title":"The extracellular matrix in ischemic and nonischemic heart failure","volume":"125","author":"Frangogiannis","year":"2019","journal-title":"Circ Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"H709","DOI":"10.1152\/ajpheart.2000.279.2.H709","article-title":"Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy","volume":"279","author":"Sen","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103572","DOI":"10.1016\/j.amsu.2022.103572","article-title":"Hypocalcemia as a cause of reversible heart failure: a case report and review of the literature","volume":"77","author":"Baqi","year":"2022","journal-title":"Ann Med Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/s41598-021-81929-7","article-title":"Low serum calcium is associated with higher long-term mortality in myocardial infarction patients from a population-based registry","volume":"11","author":"Schmitz","year":"2021","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/01.HYP.34.4.902","article-title":"Effects of aging on serum ionized and cytosolic free calcium: relation to hypertension and diabetes","volume":"34","author":"Barbagallo","year":"1999","journal-title":"Hypertension"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1297900\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T12:20:44Z","timestamp":1712146844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1297900\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":21,"alternative-id":["10.3389\/fcvm.2023.1297900"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1297900","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"article-number":"1297900"}}